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Abstract Background Chronic obstructive pulmonary dis-
ease (COPD) treatment goals are often not achieved despite
the availability of many effective treatments. Furthermore,
clinical pharmacist interventions to improve clinical and
humanistic outcomes in COPD patients have not yet been
explored and few randomized controlled trials have been
reported to evaluate the impact of pharmaceutical care on
health outcomes in patients with COPD. Objective The aim of
the present study was to evaluate the impact of pharmaceutical
care intervention, with a strong focus on self-management, on
a range of clinical and humanistic outcomes in patients with
COPD. Setting Outpatient COPD Clinic at the Royal Medical
Services Hospital. Method In a randomised, controlled, pro-
spective clinical trial, a total of 133 COPD patients were
randomly assigned to intervention or control group. A struc-
tured education about COPD and management of its symp-
toms was delivered by the clinical pharmacist for patients in
the intervention group. Patients were followed up at 6 months
during a scheduled visit. Effectiveness of the intervention was
assessed in terms of improvement in health-related quality of
life, medication adherence, disease knowledge and healthcare
utilization. Data collected at baseline and at the 6 month
assessment was coded and entered into SPSS software ver-
sion 17 for statistical analysis. A P value of\0.05 was con-
sidered statistically significant. Main outcome measure The
primary outcome measure was health-related quality of life
improvement. All other data collected including healthcare
utilization, COPD knowledge and medication adherence
formed secondary outcome measures. Results A total of 66
patients were randomized to the intervention group and 67
patients were randomized to the control group. Although the
current study failed to illustrate significant improvement in
health-related quality of life parameters, the results indicated
significant improvements in COPD knowledge (P \ 0.001),
medication adherence (P \ 0.05), medication beliefs (P \
0.01) and significant reduction in hospital admission rates
(P \ 0.05) in intervention patients when compared with
control group patients at the end of the study. Conclusion The
enhanced patient outcomes as a result of the pharmaceutical
care programme in the present study demonstrate the value of
an enhanced clinical pharmacy service in achieving the
desired health outcomes for patients with COPD.
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Impact of finding on practice
• A structured Pharmaceutical care programme led by a
clinical pharmacist for patients with COPD is associ-
ated with improved treatment outcomes.
A. S. Jarab (&)
Department of Pharmacy, Faculty of Pharmacy,
Al-Zaytoonah University of Jordan, Amman, Jordan
e-mail: anansalam10@yahoo.com
S. G. AlQudah
Department of Pharmacy, Royal Medical Services Hospital,
Amman, Jordan
M. Khdour
Department of Pharmacy, AlQuds University, Jerusalem,
Palestine
M. Shamssain
Department of Pharmacy, Health, and Wellbeing,
University of Sunderland, Sunderland, UK
T. L. Mukattash
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan
University of Science and Technology, Irbid 22110, Jordan
123
Int J Clin Pharm (2012) 34:53–62
DOI 10.1007/s11096-011-9585-z
• There is a growing need to implement a comprehensive
clinical pharmacy service for the purpose of achieving
the desired health outcomes for patients with COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is pri-
marily characterized by airflow limitation that is usually
progressive and associated with abnormal inflammatory
response of the lungs to noxious particles in addition to loss
of lung elasticity or emphysema [1, 2]. Symptoms associ-
ated with COPD usually include cough, sputum production
and shortness of breath associated with airflow obstruction.
Besides smoking, other factors such as alpha1-antitrypsin
deficiency, prolonged exposure to environmental pollutants
and recurrent respiratory infections during childhood may
precipitate COPD [3].
Currently, COPD causes approximately 2.7 million
deaths annually and it is expected to be the third leading
cause of death by disease worldwide by 2020 if successful
strategies are not implemented to prevent it [1, 4–7]. It has
been estimated that the annual death rate from the COPD
exceeds death rates from lung cancer and breast cancer
combined [8, 9].
Smoking has been defined as the leading cause of COPD
and attributed to approximately 85–90% of all cases of
COPD [3]. It has been estimated that the number of
tobacco deaths will reach more than 8 million people
worldwide per year by the year 2030, with 80% of these
premature deaths occurring in low- and middle income
developing countries including Jordan [10]. In a national
survey conducted by the Jordanian Ministry of Health, the
prevalence of cigarette use among adult males was esti-
mated to be 43% in 2004. This figure increased to 62.7% in
2007 [11–13]. Beside smoking prevalence, the lack of
knowledge of COPD among general population and the
fact that management of this illness remains suboptimal,
COPD is rapidly becoming one of the most challenging
health problems worldwide that is particularly important in
developing countries including Jordan.
Management of COPD is complex, with patients need-
ing to perform self-management process which requires
challenging behavioural and lifestyle changes such as
smoking cessation, proper use of inhalation technique,
adherence to exercise therapy along with optimal medica-
tion adherence [14]. Multiple co-morbidities are common
among patients with COPD and they are often prescribed
complex medication regimens to be administered by mul-
tiple routes for both respiratory and non respiratory con-
ditions. All these factors predispose patients to risk of non-
adherence which is considered the major reason behind
emergency hospitalisation among COPD patients. Frequent
hospital admissions due to acute exacerbation of airways
disease have been found to have a negative impact on the
quality of life of COPD patients, which is considered a
vital issue to be targeted when implementing different
interventions for patients with COPD [15–17].
Pharmacists can contribute to the care of all patients
with COPD via implementing interventions that focus on
patient education about disease, prescribed medications
and proper use of inhalation technique in addition to
ongoing assessments of patients’ willingness to adhere to
treatment recommendations and to stop smoking and
referring patients to smoking cessation programs when
necessary [18]. To the best of our knowledge, this is the
first research that investigates via a randomized, controlled,
clinical trial the impact of pharmaceutical care on COPD
patients, not only in Jordan, but within all the Middle
Eastern countries.
Aim of the study
The aim of the present study was therefore to evaluate the
impact of pharmaceutical care programme, with a strong
emphasis on self-management, on clinical and humanistic
outcomes in outpatients with COPD.
Method
Study design and subjects
The effectiveness of the pharmaceutical care intervention
was assessed through a randomised, controlled, prospective
clinical trial with a 6 month follow-up. Study subjects were
COPD patients attending an outpatient clinic at the Royal
Medical Services Hospital in Jordan. The study received
ethical approval of the Institutional Review Board, King
Hussein Hospital, Royal Medical Services, Jordan. Patients
had to meet the following inclusion criteria in order to take
part in the clinical trial: patients only attend the outpatient
COPD clinic at the Royal Medical Services, confirmed
diagnosis of COPD by the hospital consultant for at least
1 year, over 35 years old, having a forced expiratory vol-
ume in 1 s (FEV1) of 30–80% of the predicted normal
value and hospital consultant agreement that the patient is
suitable for entering the trial. Patients were excluded from
the study if they had moderate to severe learning difficul-
ties, mobility problems, confusion, disorientation or ter-
minal illness, congestive heart failure or if they attended a
pulmonary rehabilitation programme or had consulted a
pulmonary nurse or clinical pharmacist in the last
6 months. During an outpatient clinic visit, eligible patients
were informed verbally about the study by the research
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pharmacist and were provided with an information sheet.
The patients were asked to sign a consent form if they were
willing to participate in the study. Study participants were
randomly assigned to intervention and control groups via a
minimisation technique using MINIM software [19]. The
patients were recruited over a period of 3 months from
January to April, 2011.
Sample size
Based on published data [20–22], it was estimated that to
show a minimum clinically significant difference of four
points improvements in the total St. George’s Respiratory
Questionnaire (SGRQ) scores, which was considered the
primary outcome measure in the study, with a significance
level of 5% and a power of 80%, a sample size of 80
patients per group was required.
Baseline assessments
After randomisation, baseline data for each patient were
collected by the researcher pharmacist using a custom-
designed questionnaire, medical charts and hospital com-
puters. The collected data included demographic measures,
disease characteristics, respiratory and non-respiratory
medications and medication regimen and healthcare utili-
zation, i.e. emergency department (ED) visits and hospital
admissions due to exacerbation 6 months preceding the
study. The patients also completed a range of question-
naires which included: COPD knowledge questionnaire
[23], medication adherence using Morisky scale [24] and
disease-specific health-related quality of life using St
George Respiratory Questionnaire (SGRQ) [25, 26].
Follow-up assessments
Baseline data collection measures (except demographic
data) were repeated by the researcher at 6 months during
scheduled clinic visits. The primary outcome measure was
quality of life improvement. All other data collected
including healthcare utilization, COPD knowledge and
medication adherence, formed secondary outcome
measures.
Study instruments
COPD knowledge questionnaire
This instrument [23] was developed to assess patient’s
knowledge of COPD, breathing and exercise, energy con-
servation, medications, relaxation and stress control. The
COPD knowledge scale consists of 16 true/false items in
which correct responses are scored 1 and incorrect
responses are scored 0, with unsure responses receiving no
score. The range of possible scores is 0–16; the higher the
score, the greater the knowledge level.
Self-reported adherence (Morisky scale)
This simple four-question survey [24] assesses the likeli-
hood that patients take their medications as prescribed. On
scoring of the questionnaire, each ‘yes’ response is given a
score of 1 and each ‘no’ response is given a score of 0.
Adherence scores can therefore range between 0 and 4. For
the purpose of the present analysis, the patients were
divided into two groups: those scoring 0 were considered
adherent and those scoring 1–4 were considered non-
adherent.
St George Respiratory Questionnaire
The SGRQ [25, 26] is a self-administered 76-item instru-
ment designed specifically for patients with chronic air-
ways disease from which scores are calculated for three
components: symptoms, activity and impact. The scoring
range for each component is from 0 to 100, with the highest
scores indicating the poorest level of the patient’s respi-
ratory health and indicating maximum disability [27]. A
change of 4 units in the mean total score has been validated
as a clinically significant threshold [28].
The English version of both COPD knowledge [23] and
medication adherence [24] questionnaires used in the
present study was translated into Arabic as follows: (1) a
forward translation of the original questionnaire from
English into Arabic was carried out by two qualified
independent, native linguistic expert translators. (2) A back
translation from Arabic into English was carried out by two
different translators. Finally, both translations were com-
pared with the original English copy of the questionnaire
and showed more than 95% match. Furthermore, a panel of
experts in different specialties i.e. Clinical Pharmacy,
Pharmacy Practice and Respiratory Medicine examined the
research instrument for face and content validity. Pilot
work was performed and questions were adjusted as
appropriate before moving to the main study. Regarding
the SGRQ, we used a validated Arabic version of SGRQ
[29], the Arabic version was applied to 10 COPD patients
enrolled to respiratory centre at King Hussein Hospital.
Doubts and difficulties in answering the questions were
investigated. Internal consistency of symptoms, activity
and impact components was assessed using Cronbach’s
alpha (a) reliability coefficient; they were 0.94, 0.91 and
0.90, respectively. The test retest reliability of components
scores ranged from 0.70 to 0.87.
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Pharmacist intervention
A structured patient education about COPD and manage-
ment of its symptoms was delivered by the clinical phar-
macist for the intervention patients in a separate room at
the outpatient clinic. The clinical pharmacist also com-
pleted a medication table designed specifically to discuss
types, indications, doses, frequency of administration,
and possible side effects for each prescribed medication.
Furthermore, the importance of simple exercises [30],
symptoms control and the technique for expectoration [31]
were discussed with the intervention patients. A booklet on
these techniques [32] was prepared to assist in the educa-
tion session and the patients were given a copy to take
home with them. The clinical pharmacist used the moti-
vational interviewing technique [33] with the aim of
improving adherence to the prescribed treatment. Patients
who still smoked were referred to a special smoking ces-
sation programme within the hospital.
Data analysis
Data collected at baseline and at the 6 month assessments
were coded and entered into SPSS software version 17 for
statistical analysis (data screening, descriptive statistics and
univariate analysis). Data were examined using Chi-squared
analysis for categorical variables. Regarding continuous
variables, the Mann–Whitney U-test was performed for the
non-normally distributed variables and the independent
t test was performed for normally distributed variables.
A P value of\0.05 was considered statistically significant.
Results
A total of 133 COPD patients (66 intervention, 67 control)
attending an outpatient clinic were recruited into the study.
As shown in Fig. 1 below, a total of 6 patients withdrew at
the 6 month assessment; 3 patients from the intervention
group and 3 patients from the control group. Accordingly, a
total of 127 patients (63 intervention, 64 control) com-
pleted the 6 month study period.
Baseline assessments
Results indicated similar sociodemographic and clinical
characteristics between the study participants at the base-
line assessment point (Table 1). Most patients were female,
3 patients withdrew                               3 patients withdrew
133 patients recruited
66 patients assigned to 
the intervention group at 
baseline
67 patients assigned to 
the control group at 
baseline
63 intervention patients 
completed the 6 month 
assessment
64 control patients 
completed the 6 month 
assessment
Fig. 1 The total number of the
intervention and the control
patients at different stages of the
study
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elderly, married with low educational and occupational
level. Most of the study participants were current smokers
and more than half of the participants reported different co-
morbidities which included depression, diabetes, hyper-
tension, arthritis, osteoporosis, and other conditions. The
use of respiratory medications was similar between the
study groups. No difference in disease severity was
reported between the intervention and control groups at the
baseline assessment point and most of participants were
found to have moderate to severe COPD with a mean FEV1
of approximately 50% of the predicted normal value
(Table 1). No significant difference was also reported at
baseline assessment point between both groups with regard
to healthcare utilization represented by emergency
department visits and hospital admissions for acute exac-
erbation of COPD (P [ 0.05; Table 1).
Medications prescribed for study sample
The Mann–Whitney U-test revealed no significant differ-
ences (P [ 0.05) in the total number of prescribed medi-
cations between the two groups. The intervention and the
control patients were prescribed approximately the same
number of total medications over the study period. Chi-
squared analysis indicated no significant differences
(P [ 0.05) between the intervention group and the control
group in the usage of key medications at both baseline and
6 month assessments (Table 2).
Forced expiratory volume in one second
Lung function did not change from baseline to the end of the
study in either group. In the control group, the mean FEV1 was
1.08 L (CI 0.93–1.18) at the baseline assessment and 1.06 L
(CI 0.94–1.21) at 6 months assessment. Corresponding data
for the intervention group were 1.12 L (CI 0.97–1.26) and
1.15 L (CI 1.05–1.26) respectively. Accordingly, no signifi-
cant differences (P [ 0.05) in the mean FEV1 between the
intervention and control groups was observed at baseline and
over the study period as shown in Table 3.
Body mass index
There were no statistically significant differences in the
BMI values between the intervention group and control
Table 1 Baseline characteristics of study patients
Characteristics Intervention Control P value
Gender [n (%)] 0.72
Male 26 (39.4) 28 (41.8)
Female 40 (60.6) 39 (58.2)
Age (median, IQR) 61 (14) 64 (15) 0.38*
Education [n (%)] 0.83
High (University) 7 (10.6) 6 (9.0)
Low 59 (89.4) 61 (91.0)
Occupation level [n (%)] 0.91
Low 40 (60.6) 40 (59.7)
Moderate 22 (33.3) 23 (34.3)
High 4 (6.1) 4 (6.0)
Marital status [n (%)] 0.63
Married 56 (84.8) 55 (82.1)
Other 10 (15.2) 12 (17.9)
Living arrangements [n (%)] 0.52
Alone 51 (77.3) 54 (80.6)
Not alone 15 (22.7) 13 (19.4)
Smoking status [n (%)]
Current smokers 36 (54.5) 38 (56.7) 0.78
FEV1 (mean, SD) 0.81**
Liters 1.1 (0.5) 1.1 (0.5)
% predicted 53.7 (15.9) 52.8 (17.8)
FEV1/FVC 51.3 (9.5) 51.1 (10.5)
Duration of COPD
(median, IQR)
9 (7.0) 11 (8) 0.25*
Number of medication
(median, IQR)
8 (5.0) 8 (5.0) 0.98*
Co-morbid conditions
[n (%)]
53.0 (35) 55.2 (37) 0.77
Number of ED visits
(last 6 months)
61.0 66.0 0.51
Number of hospital
admissions
(last 6 months)
52.0 57.0 0.56
IQR interquartile range, FEV1 forced expiratory volume in one sec-
ond, FVC forced vital capacity, COPD chronic obstructive pulmonary
disease, ED emergency department
 Chi-squared test. * Mann–Whitney U-test. ** t test
Table 2 Prescribed medications for COPD in the intervention and
control group patients at baseline and 6-month assessment points
Prescribed
medication
[n (%)]
Baseline 6 months
Intervention Control Intervention Control
Short acting b
agonist
62 (93.9) 60 (89.6) 60 (95.2) 60 (93.8)
Long acting b
agonist
54 (81.8) 57 (85.1) 52 (82.5) 54 (84.4)
Long acting
anti-
cholinergic
46 (69.7) 44 (65.7) 47 (74.6) 46 (71.9)
Inhaled steroids 45 (68.2) 48 (71.6) 44 (69.8) 46 (71.9)
Oral steroids 6 (9.1) 8 (11.9) 8 (12.7) 8 (12.5)
Antibiotics 38 (56.7) 35 (53.0) 36 (57.1) 39 (60.9)
P value 0.62 0.78
 Chi-squared test
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group patients at the baseline and 6 month assessments in
this study (P [ 0.05; Table 3).
Knowledge of medication and disease management
As shown from the total score of COPD knowledge ques-
tionnaire, both control and intervention patients had poor
knowledge about their medication and disease management
at baseline with no statistical difference in the median
scores between the two groups (P [ 0.05). Compared with
the control group, knowledge scores were significantly
improved in the intervention group at the 6 month assess-
ment time (P \ 0.001) while it remained approximately
constant in the control group (Table 3).
Adherence to prescribed medication
At the baseline assessment, intervention group and control
group patients were found to have approximately the same
proportion of patients who exhibited low adherence
(P [ 0.05). Chi-squared analysis revealed a significant
decrease in the proportion of non-adherent patients in the
intervention group when compared with the control group
(28.6% vs. 48.4%) at the 6 month assessment (P \ 0.05;
Table 4).
Rating the effectiveness of COPD medications
Chi-squared and Fisher’s Exact tests indicated that there
was no significant differences (intervention vs. control) in
patient rating of the effectiveness of their COPD medica-
tions at baseline. There were, however, significant differ-
ences at 6 months (P \ 0.01) with an increasing number of
the intervention patients who rated their COPD medica-
tions as mostly or totally effective when compared with
control patients (Table 5).
Health-related quality of life (SGRQ)
At the baseline assessment, intervention group and control
group patients were found to have approximately the same
scores in health related quality of life parameters including
total SGRQ score and its subscales; symptoms, activity and
impact (P [ 0.05). Intervention patients showed some
improvement in total SGRQ score and its subscales at the 6
assessment; however, this improvement in quality of life
failed to reach statistical significance (P [ 0.05) as a par-
allel improvement in such parameters was reported in
patients assigned to control group (Table 6). Furthermore,
the total score at 6 months was not clinically significant as
it failed to reach the threshold of four units improvement.
Table 3 FEV1, BMI and knowledge scores for intervention and control group patients at 6-month assessment point
Variable Time Intervention Control P value
FEV1 [mean (95% CI)] Baseline 1.12 (0.97–1.26) 1.08 (0.93–1.18) 0.79**
6 months 1.15 (1.05–1.26) 1.06 (0.94–1.21) 0.55**
BMI (median, IQR) Baseline 29.3 (8.0) 28.8 (7.5) 0.72*
6 months 30.1 (8.1) 29.4 (7.8) 0.61*
Knowledge scores (median, IQR) Baseline 45.1 (27) 43.3 (20.5) 0.59*
6 months 60.7 (20) 43.6 (30) 0.007*
FEV1 forced expiratory volume in one second, CI confidence interval, BMI body mass index, IQR interquartile range
*Mann–Whitney U-test; **t test
Table 4 Self-reported medication adherence in the intervention and
the control group over the 6 month assessment period
Group Baseline 6 months
Intervention
Adherent [n (%)] 24 (36.4) 45 (71.4)
Non-adherent [n (%)] 42 (63.6) 18 (28.60)
Control
Adherent [n (%)] 27 (40.3) 33 (51.6)
Non-adherent [n (%)] 40 (59.7) 31 (48.4)
P value 0.68 0.017
 Chi-squared test
Table 5 Rating the effectiveness of COPD medications in the
intervention and the control group over the 6 month study period
Group Baseline 6 months
Intervention
Not or a little effective [n (%)] 15 (22.7) 2 (3.2)
Mostly or totally effective [n (%)] 51 (77.3) 61 (96.8)
Control
Not or a little effective [n (%)] 17 (25.4) 14 (21.9)
Mostly or totally effective [n (%)] 50 (74.6) 50 (78.1)
P value 0.76 0.008
 Chi-squared test
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Health resources utilization
Although the proportion of patients who had an emergency
department visit for acute exacerbation of COPD decreased
in the intervention group (from 16.7 to 15.2%) and
increased in the control group (from 16.4 to 17.9%) over
the study period, this change was not statistically signifi-
cant. On the other hand, statistically significant reduction in
hospital admission for acute exacerbation of COPD was
illustrated in the intervention group when compared with
the control group at the 6 month assessment point
(P \ 0.05; Table 7).
Discussion
Despite the development of effective treatments for
patients with COPD, results still suboptimal. Literature
indicates conflicting results regarding the effect of patient
education and self-management programme on improving
clinical and humanistic outcomes in patients with COPD.
Furthermore, few data are available to support the role of
clinical pharmacists in optimising therapy and improving
health outcomes in patients with COPD.
A systemic review and Meta analysis indicated that only
1 of 7 studies reported a significant improvement in lung
function in patients with COPD [34]. Consistent with this
analysis, effects of the intervention on lung function tests
in the present research were not statistically or clinically
significant. This finding can be justified by the fact that
COPD is a progressive disease characterized by irreversible
damage, and hence FEV1 is difficult to change and is not
expected to be sensitive to the intervention programme
[35].
The pharmaceutical care group in the present study
showed significant COPD knowledge improvement at the
end of the study. This finding is consistent with the findings
from Hill et al. [36] who reported a significant improve-
ment in a disease-specific knowledge in patients received
two 60 min face-to-face educational sessions at the pri-
mary care practice. Similar findings of improved COPD
knowledge have also been reported by others [22, 37]. The
significant improvement in COPD knowledge in the
intervention patients in the present study was clearly
attributed to the intensive education of intervention patients
at baseline on all aspects of COPD self-management,
combined with the regular reinforcement that those patients
received during the study.
The significant difference in medication adherence
between the two groups at the end of the study was most
likely due to the fact that intervention patients received
intensive education from the clinical pharmacist on the
dosage, therapeutic effects, safe handling, possible side
effects of their medications, in addition to an emphasis on
that the patients were able and willing to use the inhaler
devices as prescribed. Consistent with this finding, Khdour
et al. [7] reported significant improvement in medication
Table 6 Changes in SGRQ scores at 6 month assessment
Variable Symptoms Activity Impact Total score
Intervention group
Baseline (mean ± SD) 53.3 ± 18.8 57.3 ± 19.2 38.8 ± 15.8 45.2 ± 16.6
6-month change (95% CI) -2.1 (-5.4 to -0.8) -1.2 (-4.2 to 1.6) -3.4 (-7.0 to 0.2) -2.9 (-6.1 to 0.9)
Control group
Baseline (mean ± SD) 52.6 ± 17.5 57.1 ± 16.8 39.2 ± 18.2 44.8 ± 17.9
6-month change (95% CI) -1.7 (-4.6 to 1.7) -0.9 (-4.2 to 2.6) -2.8 (-6.6 to 0.5) -2.1 (-5.9 to 0.2)
P value**
Baseline 0.68 0.88 0.77 0.76
6-month change 0.59 0.68 0.54 0.51
SD standard deviation, CI confidence interval
** P value from t test
Table 7 Percentage of patients with ED visits and hospital admis-
sions during 6 months study period
Variable Control
(n = 67)
Intervention
(n = 66)
P value
ED visits for exacerbation
6 months preceding the study
16.4 16.7 0.96
ED visits for exacerbation
during 6 moths follow-up
17.9 15.2 0.79
Hospital admissions for acute
exacerbation 6 months
preceding the study
11.9 9.1 0.77
Hospital admissions for acute
exacerbation during 6 months
follow up
16.4 4.5 0.031
ED emergency department
 Chi-squared test
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adherence over a 12-month study period as a result of
clinical pharmacist-led intensive educational programme
for COPD patients attending an outpatient clinic in
Northern Ireland. Similar results also have been obtained
by Steuten et al. [38] via implementing an integrated dis-
ease management programme for patients attending Uni-
versity Hospital and 16 general practices in Netherlands.
The positive medication beliefs which was manifested
by the intervention patients was most likely due to the
motivational interviewing technique implemented by the
clinical pharmacist. This positive change might also be
related to the improved knowledge reported by the inter-
vention patients at the 6 month assessment.
Consistent with the findings from earlier research [22,
39–43], the pharmaceutical care intervention in the present
study did not have positive impact on health related quality
of life. This can be justified by the fact that the timeframe
of our study may have been too short to detect clinically
relevant changes for this parameter. Furthermore, the mean
baseline SGRQ scores for the participants in this research
was relatively low (45.2%), indicating generally good
health status of the participants which in turn decrease the
chance to detect significant improvements in health-related
quality of life. Other studies [7, 9] illustrated significant
improvement in health-related quality of life. However, the
mean baseline SGRQ scores for the participants in the two
latter studies were high (64.2%) and (54.0%) respectively,
indicating generally poor quality of life of the participants,
which in turn have increased the margin available for
improvements and hence detect differences between
groups. Furthermore, both studies [7, 9] recruited larger
number of participants when compared with the study
population in the current study. This may also have
increased the possibility to detect improvements in health
status in such earlier studies. However, it should be noted
that the effect of the intervention on quality of life have
diminished over time in these studies. This suggests the
progressive nature of the disease and indicates that moving
forward the clinical pharmacist intervention needs to
include more robust patient follow-up.
Although no significant reductions in emergency
department visits due to acute exacerbations have been
shown over the study period, the clinical pharmacist
intervention has demonstrated significant reduction in
number of patients who had hospital admissions for acute
exacerbation (from 9.8 to 5.0%) during the 6 month study
period when compared with the increased number of con-
trol group patients (from 11.3 to 15%) who had hospital
admission over the same study period (P \ 0.05). Similar
reductions in hospital admissions as a result of educational
and self-management interventions have been reported
from earlier studies [7, 43–46].
Study limitations
The study was limited in that the length of time required to
complete the battery of questionnaires used in the present
study may have encouraged bias in the responses gained
from the participants, as in an effort to finish quickly,
participants may have selected answers without giving due
consideration to the questions posed. Furthermore, social
desirability and recall bias associated with the use of a self-
report method to assess medications adherence could have
affected the results. Another limitation was that the target
sample size was not attained because the capacity for
inclusion was limited in this trial with a single investigator.
However, increasing the sample size therefore may allow
more robust conclusions to be drawn about the findings.
Conclusion
Enhanced patient outcomes as a result of the pharmaceuti-
cal care programme were obtained in the present study. This
was illustrated by decreased hospital admission rates, sig-
nificant improvement in medication adherence, improve-
ment in disease and medication knowledge and enhanced
positive attitudes toward medication effectiveness. The
present study therefore clearly demonstrated the need to
implement an integrated pharmaceutical care programmes
by the clinical pharmacists in different hospital sites in
Jordan for the purpose of improving health outcomes for
patients with COPD. More comprehensive research is
needed in this area, particularly the impact of such phar-
maceutical care programmes on the health-related quality of
life for patients with COPD in Jordan and other Middle
Eastern countries.
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